Literature DB >> 2541575

Bovine leukaemia virus ISCOMs: biochemical characterization.

M S Merza1, T Linné, S Höglund, D Portetelle, A Burny, B Morein.   

Abstract

The glycoprotein gp51 of bovine leukaemia virus (BLV) has been included in an immunostimulating complex (ISCOM). The ISCOM was characterized biochemically in SDS-polyacrylamide gel electrophoresis showing the presence of proteins of estimated molecular weights of 50 and 30 kDa. Immunoblotting showed that gp51 was present in the ISCOM. The BLV-ISCOM had a S-value of 19 S and the electronmicrograph showed the cage-like structure as previously reported for other ISCOMs. About 17% of the total amount of gp51 in the cell culture fluid was recovered in the ISCOMs. The largest loss of gp51 was encountered during the sedimentation of the virus. An ELISA, utilizing monoclonal antibodies to defined epitopes for capture was developed to control the antigenicity of epitopes, e.g. those known to induce neutralizing antibodies. Using this device as a quality control for epitopes the following could be stated. First, ISCOMs prepared from virus solubilized with the non-ionic detergents Triton X-100 or MEGA did not react with neutralizing monoclonal antibodies. In contrast, ISCOMs prepared from virus solubilized with the non-ionic detergents Tween-20, Tween-80 or octyl glucoside did react with the neutralizing antibodies. Second, the neutralizing epitopes were better exposed in ISCOMs than the other epitopes of gp51. In a preliminary experiment it was shown that gp51 in ISCOMs was highly immunogenic.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541575     DOI: 10.1016/0264-410x(89)90006-6

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Characterization of purified gp 51 from bovine leukemia virus integrated into iscom. Physicochemical properties and serum antibody response to the integrated gp51.

Authors:  M Merza; J Söber; B Sundquist; I Toots; B Morein
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Development and evaluation of a blocking enzyme-linked immunosorbent assay and virus neutralization assay to detect antibodies to viral hemorrhagic septicemia virus.

Authors:  Anna Wilson; Tony Goldberg; Susan Marcquenski; Wendy Olson; Frederick Goetz; Paul Hershberger; Lucas Hart; Kathy Toohey-Kurth
Journal:  Clin Vaccine Immunol       Date:  2014-01-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.